Rationale for Mastectomy after Neoadjuvant Chemotherapy

Area of Science:

• Oncology
• Surgical Oncology
• Breast Cancer Research

Background:

• Neoadjuvant chemotherapy (NAC) is used to reduce tumor size, potentially enabling breast-conserving surgery (BCS).
• Mastectomy remains a surgical option for some women post-NAC, even if they are candidates for BCS.
• Understanding the reasons for mastectomy after NAC in BCS-eligible patients is crucial for patient counseling and treatment decisions.

Purpose of the Study:

• To investigate the primary reasons for mastectomy in patients who received NAC, focusing on those eligible for BCS.
• To compare patient demographics and tumor characteristics between those undergoing BCS and mastectomy post-NAC.
• To identify factors associated with mastectomy in the context of neoadjuvant treatment for breast cancer.

Main Methods:

• Retrospective review of breast cancer patients who received NAC between February 2006 and August 2010.
• Comparison of demographics and tumor characteristics between patients undergoing BCS and mastectomy.
• Analysis of the specific rationales cited for mastectomy, including patient preference, disease extent, BRCA mutations, positive margins, and wound complications.

Main Results:

• Of 149 patients, 102 (68%) had BCS and 47 (32%) had mastectomy.
• Patient preference (40%), extent of disease (28%), and BRCA mutation (19%) were the leading reasons for mastectomy.
• A significant majority of mastectomy patients (79%) were eligible for BCS post-NAC.
• Larger final tumor size and lobular histology were associated with a higher rate of mastectomy.

Conclusions:

• Patient preference, disease extent, and BRCA mutations are key drivers for mastectomy after NAC, even in BCS-eligible patients.
• The findings underscore the importance of comprehensive patient education regarding surgical options and the potential benefits of BCS.
• There is a need to critically evaluate the evidence supporting more extensive surgery when breast conservation is a viable alternative after neoadjuvant chemotherapy.